261 related articles for article (PubMed ID: 21426503)
21. Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress.
Palm F; Nangaku M; Fasching A; Tanaka T; Nordquist L; Hansell P; Kawakami T; Nishijima F; Fujita T
Am J Physiol Renal Physiol; 2010 Aug; 299(2):F380-6. PubMed ID: 20519374
[TBL] [Abstract][Full Text] [Related]
22. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients.
Lee CT; Hsu CY; Tain YL; Ng HY; Cheng BC; Yang CC; Wu CH; Chiou TT; Lee YT; Liao SC
Blood Purif; 2014; 37(1):76-83. PubMed ID: 24576840
[TBL] [Abstract][Full Text] [Related]
23. Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drug-Bug Interaction?
Dai L; Meijers BK; Bammens B; de Loor H; Schurgers LJ; Qureshi AR; Stenvinkel P; Evenepoel P
Toxins (Basel); 2020 May; 12(6):. PubMed ID: 32471179
[TBL] [Abstract][Full Text] [Related]
24. Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats.
Niwa T; Yazawa T; Ise M; Sugano M; Kodama T; Uehara Y; Maeda K
Nephron; 1991; 57(1):84-8. PubMed ID: 1904558
[TBL] [Abstract][Full Text] [Related]
25. Cardiorenal syndrome: the emerging role of protein-bound uremic toxins.
Lekawanvijit S; Kompa AR; Wang BH; Kelly DJ; Krum H
Circ Res; 2012 Nov; 111(11):1470-83. PubMed ID: 23139286
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients.
Wilkes BM; Reiner D; Kern M; Burke S
Clin Nephrol; 1998 Dec; 50(6):381-6. PubMed ID: 9877112
[TBL] [Abstract][Full Text] [Related]
27. Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.
Liu WC; Tomino Y; Lu KC
Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30208594
[TBL] [Abstract][Full Text] [Related]
28. An update on protein-bound uremic retention solutes.
Vanholder R; Schepers E; Pletinck A; Neirynck N; Glorieux G
J Ren Nutr; 2012 Jan; 22(1):90-4. PubMed ID: 22200422
[TBL] [Abstract][Full Text] [Related]
29. Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats.
Niwa T; Miyazaki T; Hashimoto N; Hayashi H; Ise M; Uehara Y; Maeda K
Am J Nephrol; 1992; 12(4):201-6. PubMed ID: 1481866
[TBL] [Abstract][Full Text] [Related]
30. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys.
Miyazaki T; Ise M; Seo H; Niwa T
Kidney Int Suppl; 1997 Nov; 62():S15-22. PubMed ID: 9350672
[TBL] [Abstract][Full Text] [Related]
31. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease.
Ito S; Higuchi Y; Yagi Y; Nishijima F; Yamato H; Ishii H; Osaka M; Yoshida M
J Leukoc Biol; 2013 Jun; 93(6):837-45. PubMed ID: 23362306
[TBL] [Abstract][Full Text] [Related]
32. New insights into uremic toxicity.
Raff AC; Meyer TW; Hostetter TH
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):560-5. PubMed ID: 18941347
[TBL] [Abstract][Full Text] [Related]
33. [Uremic toxins: the case of protein-bound compounds].
Basile C; Libutti P; Teutonico A; Lomonte C
G Ital Nefrol; 2010; 27(5):498-507. PubMed ID: 20922681
[TBL] [Abstract][Full Text] [Related]
34. Roles of organic anion transporters in the progression of chronic renal failure.
Enomoto A; Niwa T
Ther Apher Dial; 2007 Oct; 11 Suppl 1():S27-31. PubMed ID: 17976081
[TBL] [Abstract][Full Text] [Related]
35. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry.
Kikuchi K; Itoh Y; Tateoka R; Ezawa A; Murakami K; Niwa T
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Nov; 878(29):2997-3002. PubMed ID: 20870466
[TBL] [Abstract][Full Text] [Related]
36. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice.
Phan O; Ivanovski O; Nguyen-Khoa T; Mothu N; Angulo J; Westenfeld R; Ketteler M; Meert N; Maizel J; Nikolov IG; Vanholder R; Lacour B; Drüeke TB; Massy ZA
Circulation; 2005 Nov; 112(18):2875-82. PubMed ID: 16267260
[TBL] [Abstract][Full Text] [Related]
37. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
Marangon N; Lindholm B; Stenvinkel P
Semin Dial; 2008; 21(5):385-9. PubMed ID: 18573137
[TBL] [Abstract][Full Text] [Related]
38. Uremic toxins: do we know enough to explain uremia?
Vanholder R; Meert N; Schepers E; Glorieux G
Blood Purif; 2008; 26(1):77-81. PubMed ID: 18182802
[TBL] [Abstract][Full Text] [Related]
39. Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate.
Viaene L; Annaert P; de Loor H; Poesen R; Evenepoel P; Meijers B
Biopharm Drug Dispos; 2013 Apr; 34(3):165-75. PubMed ID: 23300093
[TBL] [Abstract][Full Text] [Related]
40. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats.
Iwasaki Y; Yamato H; Nii-Kono T; Fujieda A; Uchida M; Hosokawa A; Motojima M; Fukagawa M
Nephrol Dial Transplant; 2006 Oct; 21(10):2768-74. PubMed ID: 16820376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
